Table 4.
Overview of ongoing (actively recruiting) phase II and III trials of antiangiogenic TKIs in NSCLCa
| Agent | Trial Description | Identifier Number |
|---|---|---|
| Sorafenib | ||
| Phase II trial of sorafenib in patients with advanced NSCLC after failure of EGFR-TKI. | NCT00922584 | |
| Phase II trial of sorafenib in combination with erlotinib in patients with advanced NSCLC after failure of chemotherapy. | NCT00801385 | |
| Phase II trial of sorafenib in patients with relapsed or refractory advanced NSCLC (nonsmokers or former light smokers). | NCT00754923 | |
| Phase III trial of third- or fourth-line sorafenib versus placebo in patients with predominantly nonsquamous NSCLC. | NCT00863746 | |
| Sunitinib | ||
| Phase II trial of first-line sunitinib in patients aged >70 years with advanced NSCLC. | NCT00864721 | |
| Phase II trial of second-line sunitinib and/or pemetrexed in patients with advanced NSCLC. | NCT00698815 | |
| Phase II trial of sunitinib in combination with cisplatin and docetaxel as salvage therapy in patients with advanced NSCLC. | NCT01019798 | |
| Phase II trial of sunitinib as maintenance therapy in patients with advanced NSCLC previously treated with combination chemotherapy. | NCT01210053 | |
| Phase III trial of sunitinib versus placebo as maintenance therapy in patients with advanced NSCLC previously treated with combination chemotherapy. | NCT00693992 | |
| Cediranib | ||
| Phase III trial of first-line cediranib in combination with carboplatin and paclitaxel in patients with advanced NSCLC (BR. 29). | NCT00795340 | |
| Phase II trial of second- or third-line cediranib in combination with pemetrexed in patients with advanced NSCLC. | NCT00410904 | |
| Vandetanib | ||
| Phase II trial of first-line vandetanib in combination with carboplatin and paclitaxel in patients with advanced NSCLC. | NCT00093392. | |
| BIBF 1120 | ||
| Phase III trial of second-line BIBF 1120 in combination with docetaxel versus docetaxel alone in patients with advanced NSCLC (LUME-Lung 1). | NCT00805194 | |
| Phase III trial of second-line BIBF 1120 in combination with pemetrexed versus pemetrexed alone in patients with advanced nonsquamous NSCLC (LUME-Lung 2). | NCT00806819 | |
| Pazopanib | ||
| Phase II/III trial of adjuvant pazopanib versus placebo in patients with stage I surgically resected NSCLC. | NCT00775307 | |
| Phase II trial of first-line pazopanib in combination with paclitaxel versus carboplatin in combination with paclitaxel in patients with advanced NSCLC. | NCT00866528 | |
| Phase II trial of second-line pazopanib in combination with erlotinib versus erlotinib alone in patients with advanced NSCLC. | NCT01027598 | |
| Phase II trial of third-line pazopanib in patients with advanced NSCLC. | NCT01049776 | |
| Axitinib | ||
| Phase II trial of first-line axitinib in combination with cisplatin and gemcitabine in patients with squamous NSCLC. | NCT00735904 | |
a
ClinicalTrials.gov accessed on November 22, 2010.
Abbreviations. EGFR: epidermal growth factor receptor; NSCLC: non-small cell lung cancer; TKI: tyrosine kinase inhibitor.